Table 2 Sample clinical characteristics
Complete sample (N =86) | Stage I (n = 12) | Stage II (n = 23) | Stage III (n = 19) | Stage IV (n = 15) | Stage V (n = 17) | |||
|---|---|---|---|---|---|---|---|---|
Variables | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Sign | |
Disease duration | 6 (7) | 2 (2) | 5 (6) | 7 (5) | 8 (7) | 10 (8) | P < 0.001 | |
Total FAS score | 15 (17) | 24 (2) | 20 (2) | 15 (4) | 5 (2) | 0 (3) | P < 0.001 | |
Independence score | 70 (35) | 97 (9) | 80 (5) | 65 (10) | 45 (20) | 20 (6) | P < 0.001 | |
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | P-value (2-sided) | ||
Comorbid conditions | 0.157 | |||||||
None | 50 (58) | 7 (8) | 10 (12) | 9 (10) | 11 (13) | 13 (15) | ||
Neurological | 1 (1.2) | 1 (1.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
Heart and vessels | 8 (9.3) | 2 (2.3) | 2 (2.3) | 2 (2.3) | 2 (2.3) | 0 (0) | ||
Lung | 2 (2.3) | 0 (0) | 0 (0) | 2 (2.3) | 0 (0) | 0 (0) | ||
Cancer | 4 (4.8) | 0 (0) | 1 (1.2) | 1 (1.2) | 1 (1.2) | 1 (1.2) | ||
Muskulosceletal | 5 (5.8) | 0 (0) | 3 (3.5) | 2 (2.3) | 0 (0) | 0 (0) | ||
Other | 9 (10.5) | 2 (2.3) | 2 (2.3) | 2 (2.3) | 0 | 3 (3.5) | ||
Multiple | 7 (8.1) | 0 (0) | 5 (5.8) | 1 (1.2) | 1 (1.2) | 0 (0) |